Exploring the Frontiers of Clinical Innovation: Bao Pharma Participating in the National Xenotransplantation Mega-Project

On 11 December 2025, China officially launched a major national science and technology project under the National Research Programme for Cancer, Cardiovascular, Respiratory and Metabolic Diseases: “Development of Medical-Grade Donor Pigs and Clinical Translational Technologies for Xenotransplantation.” The project inauguration took place in Zizhong County, Neijiang, Sichuan Province.

Led by ClonOrgan Biotechnology Co., Ltd., the initiative brings together top-tier medical and scientific institutions across China, including Xijing Hospital of the Air Force Medical University, Tongji Hospital of Tongji Medical College (Huazhong University of Science and Technology), Suzhou Hospital of Nanjing Medical University, and West China Hospital of Sichuan University—18 research institutions in total. Shanghai Bao Pharma as the only biopharmaceutical company participating in this project, has earned national-level recognition for its product pipeline and translational capabilities in transplantation, and is positioned to play an irreplaceable role in this frontier field.

Xenotransplantation: A New Frontier to Overcome Organ Shortage

Organ scarcity is a critical global medical challenge. Xenotransplantation—transplanting organs from genetically modified animals into humans—is considered one of the most promising long-term solutions for addressing the shortage of donor organs.
This national project aims to enable systematic breakthroughs across key domains, including donor pig breeding, immune-rejection regulation, and clinical translational frameworks. The ultimate goal is to accelerate the journey from laboratory research to clinical application, benefitting patients with end-stage organ failure.

Bao Pharma: Advancing Transplantation Science with Proprietary Immunomodulatory Therapeutics

Immune rejection remains the greatest barrier in xenotransplantation. To help overcome this obstacle, Bao Pharma will contribute several proprietary innovative therapeutics designed to mitigate organ rejection. These agents will be used in pig and non-human primate studies, preclinical translational work, and subsequent clinical research phases.

With extensive expertise in the discovery and manufacturing of antibody-based medicines, Bao Pharma has successfully developed and internally produced these novel candidates, establishing a strong foundation for their application in this major national research project.

Participation in this national-level key initiative marks a strategic miles***e for Bao Pharma as it continues to deepen cross-sector collaboration and expand into cutting-edge therapeutic landscapes. As the sole biopharmaceutical company in the consortium, Bao Pharma will not only provide essential investigational drugs but will also take part in designing and optimizing immunosuppressive regimens. The company will work hand-in-hand with clinicians and scientific teams to develop a uniquely Chinese approach to xenotransplantation. From supplying critical therapeutic agents to engaging in multidisciplinary technical collaboration, Bao Pharma is actively translating valuable clinical experience accumulated in highly sensitized allotransplantation into the xenotransplantation domain. The company is committed to driving xenotransplantation from scientific exploration toward clinical reality.

About Shanghai Bao Pharmaceutical

Founded in 2019, Shanghai Bao Pharmaceutical Co., Ltd. is an innovative biotechnology company specializing in clinical development, synthetic biology and recombinant biologics. The company focuses on replacing traditional biochemically extracted products and upgrading validated therapies, building a diversified pipeline across high-volume subcutaneous drug delivery, autoimmune diseases and assisted reproduction. With leading chassis-cell engineering capabilities, a stable commercial manufacturing system, and an international R&D team, Bao Pharma aims to become a global frontrunner in recombinant biologics.

Forward-Looking Statement

This press release may contain forward-looking statements based on current expectations, assumptions, and projections made by the management of Shanghai Bao Pharmaceutical Co., Ltd. (“Bao Pharma”). These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such statements include, but are not limited to, descriptions of business strategies, future operational plans, R&D progress, clinical-trial outcomes, commercial prospects, and financial performance. Except as required by law or regulation, Bao Pharma undertakes no obligation to update or revise any forward-looking statement to reflect new information, future events, or other changes. This press release is for informational purposes only and does not constitute investment advice or an offer to purchase securities of the company.